

Andrea Visentin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/875911/publications.pdf>

Version: 2024-02-01

119
papers

1,737
citations

279798

23
h-index

361022

35
g-index

122
all docs

122
docs citations

122
times ranked

2320
citing authors

#	ARTICLE	IF	CITATIONS
1	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. <i>Haematologica</i> , 2022, 107, 868-876.	3.5	31
2	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	1.7	10
3	A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 564.	2.5	0
4	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	5
5	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. <i>Haematologica</i> , 2022, 107, 1470-1473.	3.5	12
6	Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases. <i>Current Oncology</i> , 2022, 29, 1455-1460.	2.2	1
7	Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation. <i>Frontiers in Oncology</i> , 2022, 12, 835290.	2.8	2
8	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	1.3	3
9	From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. <i>Cancers</i> , 2022, 14, 1562.	3.7	9
10	Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. <i>Neurotherapeutics</i> , 2022, 19, 874-884.	4.4	10
11	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2076.	2.4	6
12	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	14
13	Anaemia during venetoclax ramp-up phase: Do not forget unusual causes. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	1.3	1
14	The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	13
15	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	5.2	2
16	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021, 35, 737-746.	7.2	61
17	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 141-144.	1.7	3
18	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	1.4	72

#	ARTICLE	IF	CITATIONS
19	Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment. <i>Blood</i> , 2021, 137, 2182-2195.	1.4	7
20	Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. <i>British Journal of Haematology</i> , 2021, 193, 316-324.	2.5	12
21	Mechanisms of Nerve Damage in Neuropathies Associated with Hematological Diseases: Lesson from Nerve Biopsies. <i>Brain Sciences</i> , 2021, 11, 132.	2.3	8
22	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	2.2	5
23	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	4.1	10
24	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. <i>PLoS ONE</i> , 2021, 16, e0247717.	2.5	10
25	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	1.7	8
26	Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, , 1.	2.8	0
27	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	4.1	8
28	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	4.1	3
29	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	1.4	30
30	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	3.7	16
31	Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. , 2021, 9, e002475.		6
32	Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6548.	2.5	2
33	Protein Kinase CK1 α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 733848.	2.8	4
34	Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 5453.	3.7	6
35	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
36	Response to Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. <i>Haematologica</i> , 2021, , .	3.5	0

#	ARTICLE	IF	CITATIONS
37	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , 2021, 138, 2641-2641.	1.4	0
38	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
39	Automated SAT Problem Feature Extraction using Convolutional Autoencoders. , 2021, , .		0
40	New responsibilities for aged kinases in B-lymphomas. <i>Hematological Oncology</i> , 2020, 38, 3-11.	1.7	8
41	<p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9679-9688.	2.0	19
42	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. <i>Hematological Oncology</i> , 2020, 38, 823-826.	1.7	16
43	From pathogenesis to personalized treatments of neuropathies in hematological malignancies. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 212-221.	3.1	7
44	A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. <i>Annals of Hematology</i> , 2020, 99, 2715-2717.	1.8	2
45	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 901-908.	2.5	17
46	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	6.2	7
47	Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3002-3005.	1.3	4
48	The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	36
49	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	2.7	4
50	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
51	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	1.4	0
52	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
53	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020, 136, 32-33.	1.4	1
54	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020, 136, 33-34.	1.4	1

#	ARTICLE	IF	CITATIONS
55	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. <i>British Journal of Haematology</i> , 2019, 185, 193-197.	2.5	24
56	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	1.7	13
57	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	3.7	16
58	Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2067-2070.	1.3	13
59	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019, 121, 150-156.	6.4	31
60	HSP70/HSF1 axis, regulated <i>via</i> a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 145, 3089-3100.	5.1	32
61	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 678-685.e4.	0.4	25
62	p66Shc deficiency in the E μ /4-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. <i>Haematologica</i> , 2019, 104, 2040-2052.	3.5	17
63	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. <i>Cancers</i> , 2019, 11, 1939.	3.7	39
64	Peripheral nervous system involvement in lymphomas. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 5-18.	3.1	44
65	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.	1.4	164
66	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. <i>Human Pathology</i> , 2019, 85, 251-259.	2.0	6
67	Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. <i>Leukemia</i> , 2019, 33, 1148-1160.	7.2	25
68	Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy. <i>European Journal of Neurology</i> , 2019, 26, 371-375.	3.3	15
69	Impact of Serum Immunoglobulin Subsets and Levels on Chronic Lymphocytic Leukemia Natural History: A Retrospective Multicentric Italian Experience. <i>Blood</i> , 2019, 134, 3026-3026.	1.4	1
70	Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs. <i>Blood</i> , 2019, 134, 3044-3044.	1.4	0
71	Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. <i>Blood</i> , 2019, 134, 1766-1766.	1.4	0
72	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018, 181, 229-233.	2.5	34

#	ARTICLE	IF	CITATIONS
73	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 20.	6.2	19
74	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , 2018, 29, 966-972.	1.2	19
75	p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β^2 -arrestin at early endosomes. <i>Oncogene</i> , 2018, 37, 1534-1550.	5.9	23
76	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. <i>American Journal of Hematology</i> , 2018, 93, 58-64.	4.1	31
77	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 366-369.	1.7	6
78	LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.	0.4	0
79	Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. <i>Annals of Hematology</i> , 2018, 97, 2001-2003.	1.8	0
80	Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , 2018, 36, 801-803.	1.7	4
81	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. <i>Blood</i> , 2018, 132, 4954-4954.	1.4	3
82	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	1.4	6
83	Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia. <i>Oncotarget</i> , 2018, 9, 32219-32231.	1.8	6
84	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. <i>Current Cancer Drug Targets</i> , 2018, 18, 608-616.	1.6	10
85	Three Different Jak2/Stat3-Related Pathways Favor the Survival of Chronic Lymphocytic Leukemia Neoplastic Clone. <i>Blood</i> , 2018, 132, 4405-4405.	1.4	0
86	Calcium Mobilization in Unfavorable-Prognosis Chronic Lymphocytic Leukemia Patients Mediates Focal Adhesion Kinase (FAK) Cleavage, Thereby Its Activation. <i>Blood</i> , 2018, 132, 5537-5537.	1.4	0
87	Monoclonal Gammopathy and Hypogammaglobulinemia As Prognostic Factors in Patients with Chronic Lymphocytic Leukemia: A Retrospective Multicentric Experience. <i>Blood</i> , 2018, 132, 5542-5542.	1.4	0
88	The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 1844-1844.	1.4	0
89	Targeting Ras-Signalling Pathway to Strike Hsf1 and Induce Apoptosis in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 5533-5533.	1.4	0
90	Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2017, 96, 159-161.	1.8	15

#	ARTICLE	IF	CITATIONS
91	Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo. <i>Cancer Cell</i> , 2017, 31, 516-531.e10.	16.8	138
92	Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e253-e256.	3.5	13
93	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2017, 178, 81-93.	2.5	25
94	Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. <i>Histopathology</i> , 2017, 71, 769-777.	2.9	29
95	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. <i>European Journal of Cancer</i> , 2017, 72, 103-111.	2.8	29
96	Nerve ultrasound abnormalities mirror the course of varicella zoster virus sensory-motor radiculoplexopathy. <i>Muscle and Nerve</i> , 2017, 55, E16-E18.	2.2	2
97	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. <i>Haematologica</i> , 2017, 102, e140-e143.	3.5	17
98	Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies. <i>European Journal of Neurology</i> , 2017, 24, 1334-1340.	3.3	9
99	Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2017, 102, 1401-1412.	3.5	23
100	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017, 35, 925-928.	1.7	19
101	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. <i>Oncotarget</i> , 2017, 8, 110727-110731.	1.8	23
102	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114.	1.8	25
103	Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. <i>Journal of Leukocyte Biology</i> , 2016, 100, 1061-1070.	3.3	14
104	Inhibition of JAK2/STAT3 Pathway Leads to Apoptosis in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2016, 128, 2023-2023.	1.4	2
105	Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University. <i>Blood</i> , 2016, 128, 2527-2527.	1.4	6
106	Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 5563-5563.	1.4	1
107	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. <i>Blood</i> , 2016, 128, 4161-4161.	1.4	0
108	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 3007-3007.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Cortactin Is a New Player in Aggressiveness and Diffusion of Chronic Lymphocytic Leukaemia. Blood, 2016, 128, 4353-4353.	1.4	1
110	HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. Blood, 2016, 128, 4368-4368.	1.4	0
111	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica, 2015, 100, e515-e518.	3.5	48
112	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget, 2015, 6, 42130-42149.	1.8	39
113	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 612-620.e5.	0.4	26
114	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and γ -tubulin inhibition by nocodazole. British Journal of Haematology, 2014, 165, 659-672.	2.5	26
115	Analysis of Major Infection Risk in 706 Patients with Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3321-3321.	1.4	0
116	Expression of FAK and Its Involvement in the Progression of B-Cell Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3309-3309.	1.4	0
117	Increased Survival and Migration of CLL B-Cells in the Presence of Marrow Mesenchymal Stromal Cells: Novel Findings for Microenvironment-Targeted Therapies. Blood, 2012, 120, 4571-4571.	1.4	5
118	Cortactin Expression Is Tightly Connected to B-Cell Chronic Lymphocytic Leukemia Aggressiveness. Blood, 2012, 120, 4561-4561.	1.4	0
119	p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF- κ B. Frontiers in Oncology, 0, 12, .	2.8	5